First published: 6:25 EST
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Shares of biotechnology company bluebird bio (NASDAQ:BLUE) erased hefty pre-market gains today, after receiving approval from the US. Food and Drug Administration (FDA) for its gene therapy Skysona. After surging more than 17% in early trading, the stock opened the regular trading in the red.
The therapy is targeted for the treatment of cerebral adrenoleukodystrophy (CALD) which is a neurodegenerative disease.
Importantly, this is the first approved therapy by the FDA that has demonstrated a slowing of progression of dysfunction in boys with CALD which is a fatal condition. The therapy is expected to be commercially available by the end of this year.
Read full Disclosure